MCFUF yields 67.97% · JNJ yields 2.13%● Live data
📍 MCFUF pulled ahead of the other in Year 1
Combined, MCFUF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MCFUF + JNJ for your $10,000?
Micro Focus International plc operates in the enterprise software business in the United Kingdom, the United States, Germany, Canada, France, Japan, and internationally. It offers infrastructure software products that are managed on a portfolio. The company's product portfolio includes sector-agnostic products, such as application modernization and connectivity solutions that help customers to unlock the value from core business applications for modernization, which enable a transformational journey to deliver ongoing value and flexibility from IT investments, on or off the mainframe; application delivery management solutions that helps customers to increase velocity, remove bottlenecks, and deliver high-performing applications to support their digital business; and IT operations management solutions for service assurance, automate the service fulfilment life cycle, and strengthen IT service governance. It also offers CyberRes, a security solution that helps enterprises to create cyber resilience through detecting threats, securing data and applications, and protecting identities, which enables customers to adapt and evolve for the future; and information management and governance solutions that helps customers to analyze, understand, and control data to derive value and manage enterprise risk. The company was founded in 1976 and is headquartered in Newbury, the United Kingdom.
Full MCFUF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.